APRIL 2016
Is There a Role for Total Prostatectomy in the Management of
Dogs with Prostatic Cancers?

Prostatic tumors are rare in dogs. The majority of canine prostatic tumors are malignant carcinomas, accounting for 98% of prostatic tumors, and include transitional cell carcinoma (TCC), adenocarcinoma, squamous cell carcinoma, and undifferentiated carcinoma. Prostatic tumors have an insidious onset and most are advanced at the time of diagnosis with 70%-80% of dogs having evidence of metastasis. The management of non-metastatic prostatic tumors is challenging because the majority of these dogs present as a result of secondary urethral obstruction or urinary tract infection.

History: An 8-month-old male intact Rottweiler presented to his rDVM for evaluation of acute onset of right hind limb (RHL) lameness following a traumatic blow while playing with another dog. Radiographs of the affected limb were normal. The problem was managed conservatively with controlled activity and carprofen, 75mg PO BID for 2 weeks. The lameness progressed to metacarpal knuckling and dragging of the leg. The patient was referred to a neurologist for further evaluation. A neurologic exam localized a lesion to the T3-L3 region with lateralization to the right side. 

Radiation Oncology Case Report:  Radiation for a Different Kind of Lymphoma
Case: Kissy, a nine-year-old, female spayed Labrador Retriever presented to her local veterinarian for foul smelling breath.  She had been previously healthy with the exception of a cranial cruciate rupture that had been successfully repaired when she was 7 years of age.  Other than her foul breath she was clinically healthy.  

The Veterinary CyberKnife Cancer Center in Malvern, PA is pleased to announce that in the summer of 2016 we will be installing a linear accelerator to compliment the radiation capabilities of the CyberKnife Stereotactic radiation therapy system. This will allow us to become one of the most comprehensive radiation facilities in the United States. Most types of solid tumors in the body can be treated using the technology available at our facility including head and neck tumors, intra-abdominal tumors, scars of incompletely excised skin cancer (STS, MCT etc). For more information, please visit  www.vetcyberknife.com  or call Dr. Siobhan Haney (radiation oncologist) at 844-738-2927. 
Researchers Turn to Canine Clinical Trials to Advance Cancer Therapies
About 6 million dogs are diagnosed with cancer each year, and more than half of dogs older than 10 years will develop cancers such as osteosarcoma, lymphoma, or melanoma.  But the heartbreaking diagnosis for dog owners is a treasure trove of potential data for oncology researchers. In clinical trials at academic research centers across the country, veterinarians and physicians are studying how pet dogs respond to cancer therapies and analyzing the genetic makeup of these tumors. Although medicine and veterinary medicine, for the most part, have been viewed as 2 different worlds, with little exchange of information between the two, that is beginning to change.

Pet Scans
Studying tumor development and treatment in dogs and cats, in parallel with research on rodents and humans, could improve the successful translation of new cancer drugs.

T he vast majority of novel anticancer compounds that show promise in laboratory studies and in animal models do not make it through the rigorous and challenging translational path necessary for approval by the US Food and Drug Administration. Multiple factors contribute to the extremely low rate of successful drug development, including unexpected toxicity and/or lack of efficacy in humans, after a candidate compound has shown promise in rodent studies. As a result, researchers have begun to develop more-accurate and more-predictive model systems, such as genetically engineered murine models or patient-derived xenograft models. 

This is a randomized trial for dogs with confirmed B-cell LSA.

Merial's B-Cell Lymphoma Vaccine, DNA, is currently undergoing clinical trials to assess its ability to prolong the post-chemotherapeutic remission time in dogs with B-cell lymphoma. The vaccine uses the same treatment concept (called xenogenic) as used in the melanoma vaccine, now the standard of care for dogs with malignant melanoma. The vaccine is designed to help stimulate the immune system to recognize and eliminate malignant B cells. The vaccine has conditional approval via the USDA and thus is deemed safe with a reasonable expectation of efficacy. Preliminary outcome data has been favorable.


Recognizing and Managing Canine and Feline Toxicities A through Z

Thursday, May 19, 2016 6:30- 8:30 pm
Hope Veterinary Specialists
Malvern, PA 

Speaker: Anna Hilton, VMD
This program is pending 1.5 hours CE from the PVMA and is open to veterinary technicians. 

Pain Management Symposium
Sunday May 22nd, 2016 8:30-2:30 pm
Season's 52
King of Prussia, PA

Keynote Speaker: Duncan Lascelles, BSc, BVSc, PhD, MRCVS, CertVA, DSAS(ST), DECVS, DACVS
Hope VS Speakers:
Brian Bretz, DVM, DACVS
Kate Vickery, VMD, MS, DACVIM, CVA

Space is limited and pre-registration is required. No on-site registration will be accommodated. This symposium is open to veterinarians. 

This programs have been submitted for 4.5 hours of continuing education credit in jurisdictions which recognize AAVSB RACE approval; however participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education.


Hope Sponsored Webinar Series


MAY 11th: Sick Oncology Cases in the ER
Presented by:  Kim Slensky, DVM, DACVECC

More information on ACVC Webinar Series »